AU2013327450B2 - Treatment of mild and moderate Alzheimer's disease - Google Patents

Treatment of mild and moderate Alzheimer's disease Download PDF

Info

Publication number
AU2013327450B2
AU2013327450B2 AU2013327450A AU2013327450A AU2013327450B2 AU 2013327450 B2 AU2013327450 B2 AU 2013327450B2 AU 2013327450 A AU2013327450 A AU 2013327450A AU 2013327450 A AU2013327450 A AU 2013327450A AU 2013327450 B2 AU2013327450 B2 AU 2013327450B2
Authority
AU
Australia
Prior art keywords
per day
disease
pct
treatment
alzheimer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013327450A
Other languages
English (en)
Other versions
AU2013327450A1 (en
Inventor
David J. Clark
Imogene M. GRIMES
Matthew J. Kostura
Cesare Orlandi
Maria Carmen Valcarce Lopez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
vTv Therapeutics LLC
Original Assignee
vTv Therapeutics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by vTv Therapeutics LLC filed Critical vTv Therapeutics LLC
Publication of AU2013327450A1 publication Critical patent/AU2013327450A1/en
Assigned to VTV THERAPEUTICS LLC reassignment VTV THERAPEUTICS LLC Alteration of Name(s) of Applicant(s) under S113 Assignors: TRANSTECH PHARMA, LLC
Assigned to VTV THERAPEUTICS LLC reassignment VTV THERAPEUTICS LLC Request for Assignment Assignors: VTV THERAPEUTICS LLC
Priority to AU2018203434A priority Critical patent/AU2018203434A1/en
Application granted granted Critical
Publication of AU2013327450B2 publication Critical patent/AU2013327450B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
AU2013327450A 2012-10-05 2013-10-02 Treatment of mild and moderate Alzheimer's disease Active AU2013327450B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2018203434A AU2018203434A1 (en) 2012-10-05 2018-05-16 Treatment of mild and moderate alzheimer's disease

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261710229P 2012-10-05 2012-10-05
US61/710,229 2012-10-05
PCT/US2013/062964 WO2014055588A1 (en) 2012-10-05 2013-10-02 Treatment of mild and moderate alzheimer's disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2018203434A Division AU2018203434A1 (en) 2012-10-05 2018-05-16 Treatment of mild and moderate alzheimer's disease

Publications (2)

Publication Number Publication Date
AU2013327450A1 AU2013327450A1 (en) 2015-05-14
AU2013327450B2 true AU2013327450B2 (en) 2018-07-12

Family

ID=49354960

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2013327450A Active AU2013327450B2 (en) 2012-10-05 2013-10-02 Treatment of mild and moderate Alzheimer's disease
AU2018203434A Abandoned AU2018203434A1 (en) 2012-10-05 2018-05-16 Treatment of mild and moderate alzheimer's disease

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2018203434A Abandoned AU2018203434A1 (en) 2012-10-05 2018-05-16 Treatment of mild and moderate alzheimer's disease

Country Status (16)

Country Link
US (3) US9717710B2 (enExample)
EP (1) EP2903606A1 (enExample)
JP (2) JP6566868B2 (enExample)
KR (1) KR20150064743A (enExample)
CN (2) CN104703592A (enExample)
AU (2) AU2013327450B2 (enExample)
BR (1) BR112015007641A8 (enExample)
CA (1) CA2886785C (enExample)
EA (1) EA201590687A1 (enExample)
HK (1) HK1207004A1 (enExample)
IL (1) IL237730B (enExample)
IN (1) IN2015DN03734A (enExample)
MX (1) MX377733B (enExample)
NZ (2) NZ705813A (enExample)
SG (2) SG11201502210VA (enExample)
WO (1) WO2014055588A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019190822A1 (en) 2018-03-28 2019-10-03 Vtv Therapeutics Llc Crystalline forms of [3-(4- {2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine
WO2019190823A1 (en) * 2018-03-28 2019-10-03 Vtv Therapeutics Llc Pharmaceutically acceptable salts of [3-(4- {2-butyl-1-[4-(4-chlorophenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine
JP7464591B2 (ja) 2018-10-10 2024-04-09 ブイティーブイ・セラピューティクス・エルエルシー ［３－（４－｛２－ブチル－１－［４－（４－クロロ－フェノキシ）－フェニル］－１ｈ－イミダゾール－４－イル｝－フェノキシ）－プロピル］－ジエチル－アミンの代謝産物
WO2020086388A1 (en) * 2018-10-22 2020-04-30 Vtv Therapeutics Llc Glucokinase activator compositions for the treatment of cognitive impairment
JP7327788B2 (ja) * 2019-08-06 2023-08-16 学校法人福岡大学 糖化産物生成抑制剤及び医薬組成物
CN114957470B (zh) * 2021-11-12 2023-01-17 深圳市人民医院 靶向rage的纳米抗体及其应用
US11648235B1 (en) 2022-12-30 2023-05-16 Cantex Pharmaceuticals, Inc. Treatment of glioblastoma

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005000295A1 (en) * 2003-05-20 2005-01-06 Transtech Pharma, Inc. Rage antagonists as agents to reverse amyloidosis and diseases associated therewith
US7361678B2 (en) * 2002-03-05 2008-04-22 Transtech Pharma, Inc. Azole derivatives and fused bicyclic azole derivatives as therapeutic agents
WO2008153957A1 (en) * 2007-06-07 2008-12-18 The Trustees Of Columbia University In The City Of New York Uses of rage antagonists for treating obesity and related diseases
US7884219B2 (en) * 2007-04-05 2011-02-08 Transtech Pharma, Inc. Crystalline forms of [3-(4- {2-butyl- 1 -[4-(4-chloro-phenoxy)-phenyl]-1H-imidazol-4-yl}-phenoxy)-propyl]-diethyl-amine

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585344A (en) 1984-03-19 1996-12-17 The Rockefeller University Liver-derived receptors for advanced glycosylation endproducts and uses thereof
EP0352581A3 (de) 1988-07-28 1990-07-04 F. Hoffmann-La Roche Ag Aethylendiaminmonoamid-Derivate
US5166214A (en) 1988-12-05 1992-11-24 Du Pont Merck Pharmaceutical Company Use of imidazoles for the treatment of atherosclerosis
US5840294A (en) 1993-03-29 1998-11-24 Queen's University At Kingston Method for treating amyloidosis
ES2170104T3 (es) 1993-10-01 2002-08-01 Merrell Pharma Inc Inhibidores de la produccion de proteinas de beta-amiloide.
US5817626A (en) 1995-03-14 1998-10-06 Praecis Pharmaceuticals Incorporated Modulators of beta-amyloid peptide aggregation
US5939526A (en) 1995-03-21 1999-08-17 Ludwig Institute For Cancer Research Isolated RAGE-1 derived peptides which complex with HLA-B7 molecules and uses thereof
WO1997026913A1 (en) 1996-01-26 1997-07-31 The Trustees Of Columbia University In The City Of New York A POLYPEPTIDE FROM LUNG EXTRACT WHICH BINDS AMYLOID-β PEPTIDE
US5864018A (en) 1996-04-16 1999-01-26 Schering Aktiengesellschaft Antibodies to advanced glycosylation end-product receptor polypeptides and uses therefor
WO1997039121A1 (en) 1996-04-16 1997-10-23 Schering Aktiengesellschaft Advanced glycosylation end-product receptor peptides and uses therefor
EP1184370B1 (en) 1996-07-22 2005-09-14 Novo Nordisk A/S Compounds with growth hormone releasing properties
US6790443B2 (en) 1996-11-22 2004-09-14 The Trustees Of Columbia University In The City Of New York Method for treating symptoms of diabetes
US7258857B2 (en) 1996-11-22 2007-08-21 The Trustees Of Columbia University In The City Of New York Rage-related methods for treating inflammation
US6555651B2 (en) 1997-10-09 2003-04-29 The Trustees Of Columbia University In The City Of New York Ligand binding site of rage and uses thereof
US5962535A (en) 1997-01-17 1999-10-05 Takeda Chemical Industries, Ltd. Composition for alzheimer's disease
US6268479B1 (en) 1997-03-12 2001-07-31 The Trustees Of Columbia University In The City Of New York Intracellular amyloid-beta peptide binding (ERAB) polypeptide
US7101838B2 (en) 1997-08-05 2006-09-05 The Trustees Of Columbia University In The City Of New York Method to prevent accelerated atherosclerosis using (sRAGE) soluble receptor for advanced glycation endproducts
US6323218B1 (en) 1998-03-11 2001-11-27 The General Hospital Corporation Agents for use in the treatment of Alzheimer's disease
US6274615B1 (en) 1998-03-25 2001-08-14 South Alabama Medical Science Foundation Method for delaying the onset of alheimer's disease and for treatment or delaying the onset of other amyloidosis-related diseases/disorders
US6465422B1 (en) 1998-04-17 2002-10-15 The Trustees Of Columbia University In The City Of New York Method for inhibiting tumor invasion or spreading in a subject
US5981168A (en) 1998-05-15 1999-11-09 The University Of British Columbia Method and composition for modulating amyloidosis
AU765142B2 (en) 1998-06-01 2003-09-11 Ortho-Mcneil Pharmaceutical, Inc. Method for treating neurodegenerative disorders
AU1199600A (en) 1998-10-02 2000-04-26 Board Of Trustees Of The University Of Illinois, The Estrogen receptor ligands
US6753150B2 (en) 1998-10-05 2004-06-22 The Trustees Of Columbia University In The City Of New York Method for determining whether a compound is capable of inhibiting the interaction of a peptide with rage
AU765719B2 (en) 1998-10-06 2003-09-25 Trustees Of Columbia University In The City Of New York, The Extracellular novel rage binding protein (EN-RAGE) and uses thereof
JP2003507013A (ja) 1999-08-13 2003-02-25 ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク βシートフィブリルのＲＡＧＥへの結合を阻害する方法及びその結果
US20010051642A1 (en) 2000-04-17 2001-12-13 Kyunghye Ahn Method for treating Alzheimer's disease
US6613801B2 (en) 2000-05-30 2003-09-02 Transtech Pharma, Inc. Method for the synthesis of compounds of formula I and their uses thereof
US6825164B1 (en) 2000-08-14 2004-11-30 The Trustees Of Columbia University In The City Of New York Method to increase cerebral blood flow in amyloid angiopathy
CA2440042C (en) 2001-03-05 2011-09-27 Transtech Pharma, Inc. Carboxamide derivatives as therapeutic agents
CN1235583C (zh) 2001-03-05 2006-01-11 特兰斯泰克制药公司 用作治疗剂的苯并咪唑衍生物
JP2006522128A (ja) 2003-04-03 2006-09-28 メルク　エンド　カムパニー　インコーポレーテッド 代謝調節型グルタミン酸受容体−５のモジュレーターとしての４環イミダゾール誘導体
CN102584813B (zh) 2003-05-14 2016-07-06 Ngc药物公司 化合物及其在调节淀粉样蛋白β中的用途
SI1703902T1 (sl) 2004-01-05 2011-02-28 Merz Pharma Gmbh & Co Kgaa Memantin za zdravljenje blage do zmerne Alzheimerjeve bolezni
DE102004050176A1 (de) 2004-09-20 2006-03-23 Universität Duisburg-Essen Optoelektronisches Bauelement und Verfahren zum Steuern von Tunnelelektronenströmen durch Photonen
US7601745B2 (en) 2004-09-27 2009-10-13 4Sc Ag Heterocyclic NF-kB inhibitors
US20070135437A1 (en) 2005-03-04 2007-06-14 Alsgen, Inc. Modulation of neurodegenerative diseases
EP1707203A1 (en) * 2005-04-01 2006-10-04 Bioprojet Treatment of parkinson's disease obstructive sleep apnea, dementia with lewy bodies, vascular dementia with non-imidazole alkylamines histamine H3- receptor ligands
WO2006124897A2 (en) 2005-05-13 2006-11-23 Lexicon Genetics Incorporated Methods and compositions for improving cognition
US20080153811A1 (en) 2006-11-07 2008-06-26 Joseph Barbosa Methods of Treating Cognitive Impairment and Dementia
CN101663280A (zh) * 2007-04-05 2010-03-03 转化技术制药公司 [3-(4-{2-丁基-1-[4-(4-氯-苯氧基)-苯基]-1h-咪唑-4-基}-苯氧基)-丙基]-二乙基-胺的晶型ⅰ和ⅱ
US20090221554A1 (en) * 2008-02-28 2009-09-03 Zenyaku Kogyo Kabushiki Kaisha Method of treating cognitive impairment
BRPI1012697A2 (pt) 2009-04-27 2016-03-29 High Point Pharmaceuticals Llc derivados imidazo[1,2-a]piridina substituídos, composições farmacêuticas, e métodos de uso como inibidores da b-secretase
CA2772797C (en) 2009-09-30 2018-09-25 Transtech Pharma, Inc. Substituted imidazole derivatives
TWI510241B (zh) 2010-02-18 2015-12-01 Vtv Therapeutice Llc 苯基－雜芳基衍生物及其使用方法
WO2012061927A1 (en) * 2010-11-08 2012-05-18 Alectos Therapeutics, Inc. Selective glycosidase inhibitors and uses thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7361678B2 (en) * 2002-03-05 2008-04-22 Transtech Pharma, Inc. Azole derivatives and fused bicyclic azole derivatives as therapeutic agents
WO2005000295A1 (en) * 2003-05-20 2005-01-06 Transtech Pharma, Inc. Rage antagonists as agents to reverse amyloidosis and diseases associated therewith
US7884219B2 (en) * 2007-04-05 2011-02-08 Transtech Pharma, Inc. Crystalline forms of [3-(4- {2-butyl- 1 -[4-(4-chloro-phenoxy)-phenyl]-1H-imidazol-4-yl}-phenoxy)-propyl]-diethyl-amine
WO2008153957A1 (en) * 2007-06-07 2008-12-18 The Trustees Of Columbia University In The City Of New York Uses of rage antagonists for treating obesity and related diseases

Also Published As

Publication number Publication date
US20170326113A1 (en) 2017-11-16
CN104703592A (zh) 2015-06-10
CA2886785C (en) 2022-06-07
MX2015003732A (es) 2015-09-23
MX377733B (es) 2025-03-11
JP2015535850A (ja) 2015-12-17
BR112015007641A8 (pt) 2018-04-03
CA2886785A1 (en) 2014-04-10
JP6566868B2 (ja) 2019-08-28
IN2015DN03734A (enExample) 2015-09-18
JP6894940B2 (ja) 2021-06-30
EP2903606A1 (en) 2015-08-12
BR112015007641A2 (pt) 2017-07-04
US20140100218A1 (en) 2014-04-10
US20190142803A1 (en) 2019-05-16
WO2014055588A1 (en) 2014-04-10
JP2019163301A (ja) 2019-09-26
AU2018203434A1 (en) 2018-06-07
CN110292638A (zh) 2019-10-01
KR20150064743A (ko) 2015-06-11
NZ739521A (en) 2019-06-28
AU2013327450A1 (en) 2015-05-14
NZ705813A (en) 2018-02-23
IL237730B (en) 2018-10-31
EA201590687A1 (ru) 2015-09-30
US9717710B2 (en) 2017-08-01
HK1207004A1 (en) 2016-01-22
SG11201502210VA (en) 2015-04-29
SG10201702648YA (en) 2017-04-27

Similar Documents

Publication Publication Date Title
US20190142803A1 (en) Treatment of Mild and Moderate Alzheimer's Disease
US20250082651A1 (en) Ganaxolone for use in treating genetic epileptic disorders
US12036190B2 (en) Methods and compositions for the treatment of cytoplasmic glycogen storage disorders
JP2026035578A (ja) ファブリー病の治療用投薬レジメン
KR102486434B1 (ko) 바독솔론 메틸 또는 이의 유사체를 사용하는 알포트 증후군의 치료 방법
EP2844279B1 (en) Dosing regimens for the treatment of pompe disease
JP2010523578A (ja) 薬理シャペロンを用いるファブリー病の治療方法
TW202142229A (zh) 治療雷葛氏症候群之病患的方法
US20130274246A1 (en) Therapeutic Treatment for Metabolic Syndrome, Type 2 Diabetes, Obesity, or Prediabetes
WO2020252129A1 (en) Methods of treating fabry disease in patients having renal impairment
EP4599894A2 (en) Methods of treating chronic spontaneous urticaria using a bruton s tyrosine kinase inhibitor
KR20220011652A (ko) 브루톤 타이로신 키나제 저해제를 사용하여 쇼그렌 증후군을 치료하는 방법
CN118284412A (zh) 伴中度至重度焦虑和/或社交回避的自闭症谱系障碍受试者易怒症的治疗
Walters et al. Early clinical experience with the novel NMDA receptor antagonist CNS 5161
Pelemans et al. Efficacy and safety of rilmenidine in elderly patients—comparison with hydrochlorothiazide
HK40009571A (zh) 治疗轻度和中度阿尔茨海默病的方法
Stever et al. Side effects of β-adrenergic antagonists and antianginal drugs
US20080261955A1 (en) Use of Pharmaceutical Compositions of Lofepramine for the Treatment of Adhd, Cfs, Fm and Depression
HK40126655A (en) Methods of treating chronic spontaneous urticaria using a bruton s tyrosine kinase inhibitor
EP4551299A1 (en) Composition for intermittent dosing of calcineurin inhibitors
HK40058710A (en) Dosing regimens for the treatment of pompe disease
HK40061328A (en) A bruton's tyrosine kinase inhibitor for use in the treatment of chronic spontaneous urticaria

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: VTV THERAPEUTICS LLC

Free format text: FORMER APPLICANT(S): VTV THERAPEUTICS LLC

FGA Letters patent sealed or granted (standard patent)